Chlorella
Green freshwater algae with small, consistent effects on cholesterol and blood pressure.
What is Chlorella?
Chlorella (Chlorella vulgaris) is a gut and immune supplement used for modestly lower ldl & total cholesterol. NutriDex grades the human evidence as Moderate. Chlorella is a protein-rich freshwater green alga sold as tablets or powder. Pooled across roughly 19 randomized trials (~800 people), supplementation produced small but statistically significant drops in total cholesterol (about 9 mg/dL), LDL (about 8 mg/dL), systolic blood pressure (about 4.5 mmHg) and fasting glucose (about 4 mg/dL), with no clear change in triglycerides, HDL or body weight. In non-alcoholic fatty liver disease, small Iranian RCTs and a meta-analysis show modest improvements in AST and glycemic markers, mostly as an add-on to standard care. An 8-week trial reported increased natural-killer-cell activity, hinting at immune effects. Limits are real: most studies are short (8–12 weeks), small, single-country and of low-to-moderate quality, and a well-conducted 1,500 mg/day diabetes RCT found no benefit. Effects are best seen as a minor metabolic nudge, not a treatment.
Purported Benefits
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Lower total and LDL cholesterolMeta-analyses (~19 RCTs) show small but significant drops (~9 mg/dL TC, ~8 mg/dL LDL); studies short and low-quality. | Moderate | ↑ benefit · small | 2 |
| Reduce blood pressurePooled 19-RCT meta-analysis found ~4.5 mmHg systolic and ~1.6 mmHg diastolic reduction. | Moderate | ↑ benefit · small | 1 |
| Improve liver enzymes/glycemia in fatty-liver diseaseSmall Iranian RCTs and a meta-analysis lowered AST and improved glucose/HOMA-IR, mostly as add-on to standard care. | Preliminary | ↑ benefit · small | 3 |
| Glycemic control in type 2 diabetesWell-conducted RCT (n=84) of 1,500 mg/day for 8 weeks found no improvement in glucose, HbA1c or lipids. | Preliminary | — no effect · negligible | 1 |
| Boost NK-cell immune activitySingle 8-week RCT (n=51) raised NK-cell activity and cytokines; isolated finding, not replicated. | Preliminary | ↑ benefit | 1 |